ClinicalTrials.gg
Status unknownNCT04744779Updated Feb 23, 2021

Office Based Vergence/Accommodative Therapy for the Treatment of Intermittent Exotropia

An interventional study of Office-based accommodative/vergence therapy and home reinforcement in Intermittent Exotropia, sponsored by Sun Yat-sen University. Status unknown. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-02-23.

Sponsored by Sun Yat-sen University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2021), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Study summary

Effectiveness of office based vergence/accommodative therapy for the treatment of intermittent exotropia is investigated through a randomized clinical trial

Read the detailed description

Purpose of study:

i) To evaluate the short-term effectiveness of office based vergence/accommodative therapy (OBVAT) for improving control of intermittent exotropia compared to observation alone; ii) To evaluate the long-term effectiveness of OBVAT for improving control of intermittent exotropia compared to observation alone; iii) To determine the natural history of intermittent exotropia among patients aged 6 to \< 18 years who have baseline near stereoacuity of 400 arc sec or better using the Preschool Randot stereotest

02

Conditions studied

  • Intermittent Exotropia

Browse trials for

03

In context

Exotropia

58 studies on the registry are indexed under Exotropia; 13 are open to participants now.

This study's planned enrollment of 40 is below the median of 50 across 49 interventional studies indexed under Exotropia.

Browse Exotropia studies →

Lead sponsor

Sun Yat-sen University is the lead sponsor of 1,690 studies on the registry; 619 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 6 to \<18 years old
  2. Distance exodeviation between 10 and 30 prism diopters (PD) measured by prism and alternate cover test (PACT)
  3. Near deviation not exceeding the distance deviation by >10PD by PACT (i.e., convergence insufficiency type intermittent exotropia excluded)
  4. Control of deviation meeting all the following criteria based on the office control score scale:

    4.1 Intermittent or constant exotropia at distance (mean of 3 baseline assessments of distance control ≥ Grade 2)# 4.2 Intermittent exotropia or exophoria at near (at least 1 of 3 assessments of near control at the baseline visit Grade 0-4) or orthophoria

  5. Stereoacuity: near stereoacuity of 400 arcsec or better by the Preschool Randot stereotest
  6. Cycloplegic subjective refraction spherical equivalent (SE) refractive error between -6.00 diopters (D)and +3.50 D inclusive in either eye
  7. Must be wearing the updated refractive correction (spectacles) for at least 2 weeks if refractive error (based on cycloplegic subjective refraction performed within 6 months) meets any of the following:

    7.1 Myopia >-0.50 D spherical equivalent in either eye 7.2 Anisometropia >1.00 D spherical equivalent 7.3 Astigmatism in either eye >1.50 D

  8. Refractive correction must meet the following guidelines:

    8.1 Anisometropia spherical equivalent must be within 0.25 D of the full anisometropic difference 8.2 Astigmatism cylinder must be within 0.25 D of full correction and axis must be within 5 degree 8.3 For hyperopia and myopia, the spherical component can be reduced by investigator discretion provided reduction is symmetrical and results in residual (i.e., uncorrected) spherical equivalent refractive error that does not exceed +3.50 D spherical equivalent hyperopia or -0.50 D spherical equivalent myopia

  9. Gestational age >34 weeks
  10. Birth weight >1500 g
  11. No previous surgical or nonsurgical treatment for intermittent exotropia other than single vision refractive correction (e.g. progressive addition lens, bifocals, patching, or deliberate over-minus with spectacles >0.50 D)
  12. No prior office-based vision therapy for any reason
  13. No prior strabismus surgery or botulinum injection, intraocular surgery, or refractive surgery
  14. No planned strabismus surgery
  15. Visual acuity correctable to at least 20/25 or better at distance and near in each eye.

    • Inclusion criteria 4.1 may be changed to "Intermittent or constant exotropia at distance (mean of 3 baseline assessments of distance control ≥ Grade 1" if there is difficulty in patient recruitment.

Exclusion criteria

Exclusion Criteria:

  1. Amblyopia, nystagmus, restrictive or paretic strabismus
  2. Regular use of any ocular or systemic medications known to affect accommodation or vergence system, such as atropine, pirenzepine, and anti-epileptic medications, in the most recent 3 months
  3. Developmental disability, attention-deficit/hyperactivity disorder (ADHD), or learning disability diagnosis in children that in the investigator's discretion would interfere with office-based treatment
  4. Relocation anticipated within 2 year
  5. Significant ocular or neurologic disorders (e.g. cerebral palsy) other than strabismus
  6. Vertical deviation greater than 3 pd
  7. Household member already in the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • No intervention
    Observation

    Observation only.

  • Experimental
    Office-based accommodative/vergence therapy and home reinforcement

    Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 16 weeks) and home reinforcement (15 minutes each time, five times per week, 16 weeks)

    Behavioral: Office-based accommodative/vergence therapy and home reinforcement

Interventions

  • BehavioralOffice-based accommodative/vergence therapy and home reinforcement

    Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 16 weeks) and home reinforcement (15 minutes each time, five times per week, 16 weeks)

06

What researchers measure

Primary outcomes

  1. Comparison of the distant office control score between two groups at the primary outcome visit

    Comparison of the distant office control score between two groups at the primary outcome visit

    Time frame: 16 months

Secondary outcomes

  1. Comparison of percentage of patients showing ≥ 1 point change and ≥ 2 points change in office control score

    Comparison of percentage of patients showing ≥ 1 point change and ≥ 2 points change in office control score

    Time frame: 16 months

Other outcomes

  1. Comparison of deterioration rate between 2 groups

    Comparison of deterioration rate between 2 groups

    Time frame: 16 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2021; primary completion for Jun 2023, 27 months later.

Of 29 interventional studies with no phase under Exotropia, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 46. This study's planned 27 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2021
First posted
Feb 9, 2021
StartEst.
Mar 2021
Primary completionEst.
Jun 2023
CompletionEst.
Jun 2023
Last update
Feb 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04744779
Collaborators
Salus University
Responsible party
Ying Kang (Associate Professor of Ophthalmology, Sun Yat-sen University) — Principal investigator
First posted
Feb 9, 2021
Start date
Mar 2021 (estimated)
Primary completion
Jun 2023 (estimated)
Completion
Jun 2023 (estimated)
Last update
Feb 23, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion